Abstract

3547Background: TAS-102 contains an antineoplastic nucleoside, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio of 1:0.5. The efficacy and safety of TAS-102 in pat...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.
Howard S Hochster ... Rocio Garcia-Carbonero
Journal of Clinical Oncology | VOL. 34
Howard S Hochster, et. al.Howard S Hochster ... Rocio Garcia-Carbonero
01 Feb 2016
Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
Yutaka Ito ... Jerome J Schentag
Current Therapeutic Research | VOL. 62
Yutaka Ito, et. al.Yutaka Ito ... Jerome J Schentag
01 Sep 2001
Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
Howard S Hochster ... Eric Van Cutsem
Journal of Clinical Oncology | VOL. 34
Howard S Hochster, et. al.Howard S Hochster ... Eric Van Cutsem
01 Feb 2016
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.
... Atsushi Ohtsu
Journal of Clinical Oncology | VOL. 34
, et. al. ... Atsushi Ohtsu
01 Feb 2016
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers